Dabrafenib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), CIPM (Spain) and G-BA (Germany), among others, recommended or restricted dabrafenib, while AOTMIT (Poland) and DMC (Denmark) did not recommend it.
Assessment has run over 11.4 years, from 27 Feb 2014 at AWMSG (Wales) to 2025 at PBAC (Australia).
HAS (France) changed its position: not recommended on 17 Apr 2019, recommended by 10 Jul 2024, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for dabrafenib.
The file is active: 14 of 38 records date from 2023 or later.
The programme is broad: 13 distinct indication wordings are recorded for dabrafenib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 38 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess dabrafenib, on 27 Feb 2014; CIPM (Spain) did not open a file until 26 Feb 2025 — an unusually long tail of 11 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 11 years in total.
10 of the 14 agencies here assessed dabrafenib more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
dabrafenib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for dabrafenib reads 21 recommended, 5 not recommended, 4 deferred to NICE and 2 restricted, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Non-small cell lung cancer (NSCLC) | Recommended | source |
| CIPM (Spain) | 26 Feb 2025 | Indicaciones terapéuticas autorizadas: Glioma de bajo grado Finlee, en combinación con trametinib, está indicado para el… | financed by the SNS · art. 92 a, b, c | source |
| TLV (Sweden) | 17 Oct 2024 | Finlee och Spexotras ingår i högkostnadsskyddet | general subsidy | source |
| NYE METODER (Norway) | 21 May 2023 | Kombinasjonsbehandling til voksne pasienter med ikke-småcellet lungekreft som har progrediert etter behandling med kjemo… | not introduced | source |
| G-BA (Germany) | 19 Oct 2017 | Tafinlar — benefit assessment §35a | added benefit: not proven | source |
33 further decisions for dabrafenib, across 13 agencies, are not shown here. They link to 27 further source documents.
Related molecules
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
Coverage: 38 decisions for dabrafenib from 14 agencies, 2014 to 2025. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.